FDA Vouchers Fast-Track Psychedelic Drugs for Depression and PTSD – Psych Congress Responds With Expert Briefing
Key Clinical Summary
- The US Food and Drug Administration, following an executive order, announced new regulatory actions to reduce drug review timelines to 1 to 2 months for psychedelic therapies targeting major depression and substance use disorders.
- Compass Pathways’ COMP360 for treatment-resistant depression has completed phase 3 investigation, Usona Institute’s PSIL201 for major depressive disorder is in phase 3 investigation, and Transcend Therapeutics’ TSND-201 for posttraumatic stress disorder (PTSD) met its primary endpoint in a phase 2 study in July 2025.
- The US Food and Drug Administration authorized an early-phase Investigational New Drug study of ibogaine for alcohol use disorder, while noting the need for robust trial design, safety monitoring, and supervised administration before clinical implementation.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions, including major depression and substance use disorders (SUDs).
These developments may affect future treatment options for psychiatrists and addiction specialists managing patients with treatment-resistant conditions.
“There is a growing recognition of the potential of psychedelic medications to address multiple different psychiatric conditions that are notoriously difficult to treat,” said Tracy Beth Hoeg, MD, PhD, Acting Director, FDA Center for Drug Evaluation and Research, in a press release. “At the FDA we are showing our support of investigating the safety and efficacy of this class of drugs through today’s actions.”
FDA Priority Vouchers for Psychedelic Drugs
Three companies received national priority vouchers for study of serotonin-2A agonists previously granted Breakthrough Therapy designation:
- Compass Pathways for COMP360, a proprietary formulation of synthetic psilocybin for treatment-resistant depression that has completed phase 3 investigation
- Usona Institute for PSIL201, a psilocybin treatment for major depressive disorder (MDD) that is currently in phase 3 investigation
- Transcend Therapeutics for TSND-201, a methylone treatment for posttraumatic stress disorder (PTSD) which met its primary endpoint in a phase 2 study in July 2025
The Commissioner’s National Priority Voucher Pilot Program, announced in June 2025, seeks to “dramatically reduce” drug application review and approval timelines to within 1-2 months. Eligible products must align with 1 of 5 “critical US national health priorities,” including public health crisis response and innovative breakthrough therapies.
The FDA has also authorized an early-phase clinical study of ibogaine via the Investigational New Drug pathway to explore its potential as a treatment for alcohol use disorder. It is the first time that the agency has allowed clinical study of the drug in the United States.
Concerns About Trial Design, Safety, and Access
Further guidance and recommendations on how best to develop serotonin-2A agonists for mental health treatment are forthcoming, the FDA announced. “Unique scientific and methodological challenges” accompany study of this drug class, such as the question of functional unblinding that plagued Lykos’ failed drug application for midomafetamine (MDMA) for PTSD in August 2024.
Accordingly, the final guidelines will feature robust recommendations on study design, data collection, and patient monitoring.
Despite accelerated development, access will depend on regulatory approval, provider training, and infrastructure for supervised administration
Psych Congress Faculty Experts Weigh In
The recent wave of executive initiative marks a new era for psychedelic-assisted therapies in mental health treatment and with it an imperative for clinicians to expand their knowledge on the topic.
“There are several key differences from prior times when enthusiasm for psychedelics outran the actual situation in terms of their development,” Charles Raison, MD, Director of Clinical and Translation Research at Usona Institute and Psych Congress Steering Committee Member, told Psych Congress Network via email “At least 1 pharmaceutical company—in this case Compass—has data from 2 adequate phase 3 studies [which] have from the beginning been conducted in a manner that will make FDA much more likely to approve them.
“The other key difference is that political power in the US is now fully behind the rapid approval of psychedelics when appropriate data are available.”
“If a clinician has been standing on the sidelines, waiting to see what will happen, I completely understand their potential skepticism,” said Andrew Penn, PMHNP-BC, Psych Congress Steering Committee Member, told PCN. “It’s looking more likely [though] that 1 or more of these compounds will be available for clinical use in the next year or so.
“It’s still not entirely clear what the FDA or Risk Evaluation and Mitigation Strategies (REMS) will require, but it’s reasonable for clinicians to prepare themselves for a model that uses a brief period of a supervised, non-ordinary state of consciousness as part of the treatment modality.”
Psych Congress Expert Briefing
In response to the Executive Order and FDA announcement, Psych Congress is presenting an expert briefing for psychiatric and behavioral health professionals navigating the rapidly evolving psychedelic-assisted therapy space. The free simulcast, “Psychedelic Countdown: From Clinical Trials to Clinical Practice,” will feature an exclusive Q&A session with Psych Congress faculty experts Dr Raison and Penn, today, April 29th at 6:00 PM EST.
This timely discussion will examine the significance of recent regulatory developments and actionable steps that clinicians can take to prepare for patient questions about and clinical application of these therapies today.
Are You Ready for Psychedelic Treatment? Register now!
References
